West on Lung Cancer

H. Jack West, MD, is an Associate Clinical Professor and the Executive Director of Employer Services at City of Hope Comprehensive Cancer Center in Duarte, CA. He is also the web editor of JAMA Oncology and the founder and president of the nonprofit organization Global Resource for Advancing Cancer Education (GRACE), which provides information for patients and caregivers dealing with cancer. Dr West leads a wide range of continuing medical education programs and other educational programs, including hosting the audio podcast, West Wind.

+ Add to Email Alerts

'Aspirationally Resectable'? Neoadjuvant Tx Evolves in NSCLC H. Jack West, MD, and Julia Rotow, MD, discuss clinical implications of thoracic oncology research presented at ASCO 2023.
Medscape Oncology, September 18, 2023
Unless It Improves Survival, More Is Not Better Dr Jack West asks whether combination therapy is a true advance if we are simply giving multiple treatments at once, particularly if it doesn't translate to a patient living longer.
Medscape Oncology, September 15, 2023
For NSCLC, Neoadjuvant, Adjuvant, or Both? H. Jack West, MD, and Julia Rotow, MD, discuss data on perioperative approaches presented at ASCO 2023.
Medscape Oncology, August 04, 2023
Jack West and Julia Rotow Discuss ADAURA Trial Takeaways At ASCO 2023, the ADAURA trial made headlines in lung cancer. But does it raise more questions than it answers?
Medscape Oncology, June 13, 2023
Did an Unfair System Help ADAURA Win on Overall Survival? Jack West, MD, discusses the problematic design and ethical issues of the ADAURA trial.
Medscape Oncology, June 08, 2023
The Upside of Rejection Jack West, MD, discusses how rejection can be challenging but often makes us better.
Medscape Oncology, May 31, 2023
When Practice-Changing Results Don't Change Practice Oncologist Jack West explores the barriers to accepting and implementing practice-changing evidence.
Medscape Oncology, March 30, 2023
Local Therapies Show Promise for Metastatic Lung Cancer New studies are challenging old dogma when it comes to local therapy for advanced lung cancer, argues Jack West, MD.
Medscape Oncology, February 14, 2023
The Fix We Need to Break the Impasse in Precision Oncology The interpretation of NGS test results warrants its own specialized service akin to "nighthawk" radiology, argues Jack West.
Medscape Oncology, December 15, 2022
Discontinuing Immunotherapy: Half Empty or Half Full? Thoracic oncologist Jack West discusses the nuances of discontinuing immunotherapy in patients with NSCLC with a positive response at 2 years.
Medscape Oncology, November 21, 2022
Discerning Bias in Cancer News Oncologist Jack West critiques medical journalism written without balance and rigor, either accidentally or not.
Medscape Oncology, November 17, 2022
How Would You Treat Your Spouse? Practical but Not Hard Evidence Most cancer patients are looking for a recommendation based on insight, not clinical trial statistics, oncologist Jack West argues.
Medscape Oncology, November 16, 2022
We Are Rebranding Suboptimal Care as Real-World Practice Oncologist Jack West reflects on a growing paradigm of omitting adjuvant chemotherapy from clinical trials and standard care of early-stage NSCLC.
Medscape Oncology, October 25, 2022
Live Meetings: Is the Juice Still Worth the Squeeze? Are live meetings worth the cost and hassle of travel, let alone the risk for COVID?
Medscape Oncology, August 01, 2022
Why Is Adhering to Standard of Care So Elusive? Oncologist Jack West, MD, explores the chasm between recommendations and clinical practice.
Medscape Oncology, June 22, 2022
Twitter Polls: Tapping Into the Wisdom of Crowds Oncologist Jack West explores the powerful benefits of Twitter polls.
Medscape Oncology, April 14, 2022
Is a PFS Benefit Alone Really Worth $10,000 a Month? Oncologist H. Jack West explores whether and when to consider surrogate endpoints to be practice-changing.
Medscape Oncology, March 02, 2022
Swinging for the Fences: Curing NSCLC Oncologist Jack West explores the major advances we've made in treating NSCLC and makes predictions for what's to come in the curative setting.
Medscape Oncology, January 20, 2022
Too Soon to Utter the Word 'Cure' in Advanced Lung Cancer? Oncologist Jack West explores whether it's appropriate to use the word "cure" for some patients with advanced lung cancer.
Medscape Oncology, November 16, 2021
When Phase 3 Data Can't Guide Oncology Decision-Making Oncologist Jack West explores the limits of phase 3 data to provide clear treatment options for the many subgroups of patients.
Medscape Oncology, October 14, 2021

No Results